Evidence map›Paper›PMID 36827977›Full record

ReviewStem cell reports2023

Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan.

Tsunakuni Ikka, Misao Fujita, Taichi Hatta, Tetsu Isobe, Kenji Konomi, Tatsuo Onishi, Shoji Sanada, Yuichiro Sato, Shimon Tashiro, Morikuni Tobita

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Amendment ofRegenerative therapy · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Tsunakuni IkkaDivision of Bioethics & Healthcare Law, Institute for Cancer Control, National Cancer Center Japan, Chuo-ku, Tokyo 104-0045, Japan; Division of Bioethics, Center for Research Administration and Support, National Cancer Center Japan, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: tikka@ncc.go.jp.
Misao FujitaUehiro Research Division for iPS Cell Ethics, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), KUIAS, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: misao-fujita@cira.kyoto-u.ac.jp.
Taichi HattaGraduate School of Public Health, Shizuoka Graduate University of Public Health, Aoi-ku, Shizuoka 420-0881, Japan.
Tetsu IsobeLaw School, Keio University, Minato-ku, Tokyo 108-8345, Japan.
Kenji KonomiClinical and Translational Research Center, Keio University Hospital, Shinjuku-ku, Tokyo 160-0016, Japan.
Tatsuo OnishiMLIP Law Office, Minato-ku, Tokyo 105-0004, Japan.
Shoji SanadaClinical and Translational Research Center, Kobe University Hospital, Kobe-city, Hyougo 650-0017, Japan.
Yuichiro SatoFaculty of Education, Tokyo Gakugei University, Koganei-city, Tokyo 184-8501 Japan.
Shimon TashiroDepartment of Sociology, Graduate School of Arts and Letters, Tohoku University, Sendai, Miyagi 980-8567, Japan.
Morikuni TobitaMedical Technology Innovation Center, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan.
Juntendo University · JPKeio University · JPKeio University Hospital · JPKobe University Hospital · JPKyoto University · JPNational Cancer Research Institute · GBTohoku University · JPTokyo Gakugei University · JPUniversity of Shizuoka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We outlined five studies regarding the quality of the review by committees based on the Act on the Safety of Regenerative Medicine. The findings raise serious concerns about the independence, integrity, and quality of reviews of therapeutic plans by these committees with inappropriately close relationships to medical institutions and companies.

Indexed as

Regenerative MedicineJapan

Identifiers

PMID36827977
PMCPMC10031296
OpenAlexW4321613229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.